On Jan. 19, 2017, PharmAthene and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, announced an agreement for the merger of PharmAthene and Altimmune in an all-stock transaction.

The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs.